Therapeutic drug monitoring of lamotrigine;Suivi thérapeutique pharmacologique de la lamotrigine

Therapie

Volumn 65, Issue 1, 2010, Pages 39-46

  Bentué Ferrer, Danièle ^a   Tribut, Olivier ^a   Verdier, Marie Clémence ^a  

^a PONTCHAILLOU UNIVERSITY HOSPITAL   (France)

Author keywords

Lamotrigine; Therapeutic drug monitoring

Indexed keywords

ARIPIPRAZOLE; CARBAMAZEPINE; CIMETIDINE; ETHINYLESTRADIOL; FELBAMATE; LAMOTRIGINE; LOPINAVIR PLUS RITONAVIR; OLANZAPINE; ORAL CONTRACEPTIVE AGENT; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; PRIMIDONE; RIFAMPICIN; SERTRALINE; TOPIRAMATE; VALPROIC ACID; VIGABATRIN; ZONISAMIDE;

AREA UNDER THE CURVE; BIPOLAR I DISORDER; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MONITORING; EPILEPSY; GILBERT DISEASE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; KIDNEY FAILURE; LIQUID CHROMATOGRAPHY; LIVER FAILURE; MASS SPECTROMETRY; MAXIMUM PLASMA CONCENTRATION; NEUROPATHIC PAIN; PREGNANCY; PRIORITY JOURNAL; REVIEW; TIME TO MAXIMUM PLASMA CONCENTRATION;

EID: 77949429096     PISSN: 00405957     EISSN: None     Source Type: Journal    
DOI: 10.2515/therapie/2009063     Document Type: Article

References (81)

1. Résumé des Caractéristiques du Produit de la lamotrigine. Éditions du Vidal, 2008
2. Rheims S, Ryvlin P. Once-daily lamotrigine extended release for epilepsy management. Expert Rev Neurother 2009; 9: 167-173
3. Goldsmith DR, Wagstaff AJ, Ibbotson T, et al. Lamotrigine: a review of its use in bipolar disorder. Drugs 2003; 63: 2029-2050
4. Titlic M, Jukic I, Tonkic A, et al. Lamotrigine in the treatment of pain syndromes and neuropathic pain. Bratisl Lek Listy 2008; 109: 421-424
5. Biton V. Pharmacokinetics, toxicology and safety of lamotrigine in epilepsy. Expert Opin Drug Metab Toxicol 2006; 2: 1009-1018
6. Fitton A, Goa KL. Lamotrigine. An update of its pharmacology and therapeutic use in epilepsy. Drugs 1995; 50: 691-713
7. Goa KL, Ross SR, Chrisp P. Lamotrigine. A review of its pharmacological properties and clinical efficacy in epilepsy. Drugs 1993; 46: 152-176
8. Matsuo F. Lamotrigine. Epilepsia 1999; 40 Suppl 5: S30-36
9. Walker MC, Sander JW. Lamotrigine. Antiepileptic drugs 1999; 138: 351-358
10. Cohen AF, Land GS, Breimer DD, et al. Lamotrigine, a new anticonvulsant: pharmacokinetics in normal humans. Clin Pharmacol Ther 1987; 42: 535-541
11. Lardizabal DV, Morris HH, Hovinga CA, et al. Tolerability and pharmacokinetics of oral loading with lamotrigine in epilepsy monitoring units. Epilepsia 2003; 44: 536-539
12. Chen C, Casale EJ, Duncan B, et al. Pharmacokinetics of lamotrigine in children in the absence of other antiepileptic drugs. Pharmacotherapy 1999; 19: 437-441
13. Garnett WR. Lamotrigine: pharmacokinetics. J Child Neurol 1997; 12 Suppl 1: S10-15
14. Rambeck B, Wolf P. Lamotrigine clinical pharmacokinetics. Clin Pharmacokinet 1993; 25: 433-443
15. Sharma C, Dubey R, Kumar H, et al. Food reduces the bioavailability of lamotrigine. Indian J Med Res 2005; 121: 659-664
16. Peck AW. Clinical pharmacology of lamotrigine. Epilepsia 1991; 32 Suppl 2: S9-12
17. Incecayir T, Agabeyoglu I, Gucuyener K. Comparison of plasma and saliva concentrations of lamotrigine in healthy volunteers. Arzneimittelforschung 2007; 57: 517-521
18. Malone SA, Eadie MJ, Addison RS, et al. Monitoring salivary lamotrigine concentrations. J Clin Neurosci 2006; 13: 902-907
19. Tsiropoulos I, Kristensen O, Klitgaard NA. Saliva and serum concentration of lamotrigine in patients with epilepsy. Ther Drug Monit 2000; 22: 517-521
20. Hussein Z, Posner J. Population pharmacokinetics of lamotrigine monotherapy in patients with epilepsy: retrospective analysis of routine monitoring data. Br J Clin Pharmacol 1997; 43: 457-465
21. Ramsay RE, Pellock JM, Garnett WR, et al. Pharmacokinetics and safety of lamotrigine (Lamictal) in patients with epilepsy. Epilepsy Res 1991; 10: 191-200
22. Reinsberger C, Dorn T, Kramer G. Smoking reduces serum levels of lamotrigine. Seizure 2008; 17: 651-653
23. Liporace J, Kao A, D'Abreu A. Concerns regarding lamotrigine and breastfeeding. Epilepsy Behav 2004; 5: 102-105
24. Ohman I, Vitols S, Tomson T. Lamotrigine in pregnancy: pharmacokinetics during delivery, in the neonate, and during lactation. Epilepsia 2000; 41: 709-713
25. Kilpatrick ES, Forrest G, Brodie MJ. Concentration-effect and concentrationtoxicity relations with lamotrigine: a prospective study. Epilepsia 1996; 37: 534-538
26. Gidal BE, Welty TE. The concentration-effect relationship with lamotrigine (LTG). Epilepsia 1997; 38: 260
27. Schapel GJ, Black AB, Lam EL, et al. Combination vigabatrin and lamotrigine therapy for intractable epilepsy. Seizure 1996; 5: 51-56
28. Bartoli A, Guerrini R, Belmonte A, et al. The influence of dosage, age, and comedication on steady state plasma lamotrigine concentrations in epileptic children: a prospective study with preliminary assessment of correlations with clinical response. Ther Drug Monit 1997; 19: 252-260
29. Benetello P, Furlanut M, Baraldo M, et al. Therapeutic drug monitoring of lamotrigine in patients suffering from resistant partial seizures. Eur Neurol 2002; 48: 200-203
30. Sondergaard Khinchi M, Nielsen KA, Dahl M, et al. Lamotrigine therapeutic thresholds. Seizure 2008; 17: 391-395
31. Kanner A, Chkenkely I, Frey M. Is there a relationship between the occurence of adverse events from lamotrigine and its serum concentrations. Epilepsia 1998; 39, Suppl.6: 72-73
32. Fröscher W, Keller F, Vogt H, et al. Prospective study on concentrationefficacy and concentration-toxicity: correlations with lamotrigine serum levels. Epileptic Disord 2002; 4: 49-56
33. Hirsch LJ, Weintraub D, Du Y, et al. Correlating lamotrigine serum concentrations with tolerability in patients with epilepsy. Neurology 2004; 63: 1022-1026
34. Willis T, Roper H, Rabb L. Lamotrigine poisoning presenting as seizures: a case of deliberate poisoning. Child Abuse Negl 2007; 31: 85-88
35. Mikati MA, Fayad M, Koleilat M, et al. Efficacy, tolerability, and kinetics of lamotrigine in infants. J Pediatr 2002; 141: 31-35
36. Reimers A, Skogvoll E, Sund JK, et al. Lamotrigine in children and adolescents: the impact of age on its serum concentrations and on the extent of drug interactions. Eur J Clin Pharmacol 2007; 63: 687-692
37. Punyawudho B, Ramsay RE, Macias FM, et al. Population pharmacokinetics of lamotrigine in elderly patients. J Clin Pharmacol 2008; 48: 455-463
38. Wootton R, Soul-Lawton J, Rolan PE, et al. Comparison of the pharmacokinetics of lamotrigine in patients with chronic renal failure and healthy volunteers. Br J Clin Pharmacol 1997; 43: 23-27
39. Fillastre JP, Taburet AM, Fialaire A, et al. Pharmacokinetics of lamotrigine in patients with renal impairment: influence of haemodialysis. Drugs Exp Clin Res 1993; 19: 25-32
40. Marcellin P, de Bony F, Garret C, et al. Influence of cirrhosis on lamotrigine pharmacokinetics. Br J Clin Pharmacol 2001; 51: 410-414
41. Tran TA, Leppik IE, Blesi K, et al. Lamotrigine clearance during pregnancy. Neurology 2002; 59: 251-255
42. de Haan GJ, Edelbroek P, Segers J, et al. Gestation-induced changes in lamotrigine pharmacokinetics: a monotherapy study. Neurology 2004; 63: 571-573
43. Petrenaite V, Sabers A, Hansen-Schwartz J. Individual changes in lamotrigine plasma concentrations during pregnancy. Epilepsy Res 2005; 65: 185-188
44. Franco V, Mazzucchelli I, Gatti G, et al. Changes in lamotrigine pharmacokinetics during pregnancy and the puerperium. Ther Drug Monit 2008; 30: 544-547
45. Pennell PB, Peng L, Newport DJ, et al. Lamotrigine in pregnancy: clearance, therapeutic drug monitoring, and seizure frequency. Neurology 2008; 70: 2130-2136
46. Fotopoulou C, Kretz R, Bauer S, et al. Prospectively assessed changes in lamotrigine-concentration in women with epilepsy during pregnancy, lactation and the neonatal period. Epilepsy Res 2009; 85: 60-64
47. Ohman I, Beck O, Vitols S, et al. Plasma concentrations of lamotrigine and its 2-N-glucuronide metabolite during pregnancy in women with epilepsy. Epilepsia 2008; 49: 1075-1080
48. Chen H, Yang K, Choi S, et al. Up-regulation of UDP- glucuronosyltransferase (UGT) 1A4 by 17beta-estradiol: a potential mechanism of increased lamotrigine elimination in pregnancy. Drug Metab Dispos 2009; 37: 1841-1847
49. Posner J, Cohen AF, Land G, et al. The pharmacokinetics of lamotrigine (BW430C) in healthy subjects with unconjugated hyperbilirubinaemia (Gilbert's syndrome). Br J Clin Pharmacol 1989; 28: 117-120
50. Paul F, Veauthier C, Fritz G, et al. Perioperative fluctuations of lamotrigine serum levels in patients undergoing epilepsy surgery. Seizure 2007; 16: 479-484
51. Schieber FC, Boulton DW, Balch AH, et al. A non-randomized study to investigate the effects of the atypical antipsychotic aripiprazole on the steadystate pharmacokinetics of lamotrigine in patients with bipolar I disorder. Hum Psychopharmacol 2009; 24: 145-152
52. Koch HJ, Szecsey A, Vogel M. Clinically relevant reduction of lamotrigine concentrations by carbamazepine. Eur Psychiatry 2003; 18: 42
53. Sabers A, Ohman I, Christensen J, et al. Oral contraceptives reduce lamotrigine plasma levels. Neurology 2003; 61: 570-571
54. Sabers A, Buchholt JM, Uldall P, et al. Lamotrigine plasma levels reduced by oral contraceptives. Epilepsy Res 2001; 47: 151-154
55. Herzog AG, Blum AS, Farina EL, et al. Valproate and lamotrigine level variation with menstrual cycle phase and oral contraceptive use. Neurology 2009; 72: 911-914
56. Ebert U, Thong NQ, Oertel R, et al. Effects of rifampicin and cimetidine on pharmacokinetics and pharmacodynamics of lamotrigine in healthy subjects. Eur J Clin Pharmacol 2000; 56: 299-304
57. Reimers A, Helde G, Brodtkorb E. Ethinyl estradiol, not progestogens, reduces lamotrigine serum concentrations. Epilepsia 2005; 46: 1414-1417
58. Colucci R, Glue P, Holt B, et al. Effect of felbamate on the pharmacokinetics of lamotrigine. J Clin Pharmacol 1996; 36: 634-638
59. Gidal BE, Kanner A,Maly M, et al. Lamotrigine pharmacokinetics in patients receiving felbamate. Epilepsy Res 1997; 27: 1-5
60. van der LeeMJ, Dawood L, ter Hofstede HJ, et al. Lopinavir/ritonavir reduces lamotrigine plasma concentrations in healthy subjects. Clin Pharmacol Ther 2006; 80: 159-168
61. JannMW, Hon YY, Shamsi SA, et al. Lack of pharmacokinetic interaction between lamotrigine and olanzapine in healthy volunteers. Pharmacotherapy 2006; 26: 627-633
62. Sidhu J, Job S, Bullman J, et al. Pharmacokinetics and tolerability of lamotrigine and olanzapine coadministered to healthy subjects. Br J Clin Pharmacol 2006; 61: 420-426
63. Theis JG, Sidhu J, Palmer J, et al. Lack of pharmacokinetic interaction between oxcarbazepine and lamotrigine. Neuropsychopharmacology 2005; 30: 2269-2274
64. Kaufman KR, Gerner R. Lamotrigine toxicity secondary to sertraline. Seizure 1998; 7: 163-165
65. Berry DJ, Besag FM, Pool F, et al. Lack of an effect of topiramate on lamotrigine serum concentrations. Epilepsia 2002; 43: 818-823
66. Doose DR, Brodie MJ, Wilson EA, et al. Topiramate and lamotrigine pharmacokinetics during repetitive monotherapy and combination therapy in epilepsy patients. Epilepsia 2003; 44: 917-922
67. Yuen AW, Land G, Weatherley BC, et al. Sodium valproate acutely inhibits lamotrigine metabolism. Br J Clin Pharmacol 1992; 33: 511-513
68. Kanner AM, Frey M. Adding valproate to lamotrigine: a study of their pharmacokinetic interaction. Neurology 2000; 55: 588-591
69. Levy RH, Ragueneau-Majlessi I, Brodie MJ, et al. Lack of clinically significant pharmacokinetic interactions between zonisamide and lamotrigine at steady state in patients with epilepsy. Ther Drug Monit 2005; 27: 193-198
70. Cheng CL, Chou CH, Hu OY. Determination of lamotrigine in small volumes of plasma by high-performance liquid chromatography. J Chromatogr B Analyt Technol Biomed Life Sci 2005; 817: 199-206
71. Brunetto Mdel R, Contreras Y, Delgado Y, et al. Development and validation of a rapid column-switching high-performance liquid chromatographic method for the determination of lamotrigine in human serum. J Chromatogr Sci 2009; 47: 478-484
72. Bompadre S, Tagliabracci A, Battino M, et al. Determination of lamotrigine in whole blood with on line solid phase extraction. J Chromatogr B Analyt Technol Biomed Life Sci 2008; 863: 177-180
73. Saracino MA, Bugamelli F, Conti M, et al. Rapid HPLC analysis of the antiepileptic lamotrigine and its metabolites in human plasma. J Sep Sci 2007; 30: 2249-2255
74. Zufia L, Aldaz A, Ibanez N, et al. LC method for the therapeutic drug monitoring of lamotrigine: evaluation of the assay performance and validation of its application in the routine area. J Pharm Biomed Anal 2009; 49: 547-553
75. Vermeij TA, Edelbroek PM. Robust isocratic high performance liquid chromatographic method for simultaneous determination of seven antiepileptic drugs including lamotrigine, oxcarbazepine and zonisamide in serum after solid-phase extraction. J Chromatogr B Analyt Technol Biomed Life Sci 2007; 857: 40-46
76. Greiner-Sosanko E, Giannoutsos S, Lower DR, et al. Drug monitoring: simultaneous analysis of lamotrigine, oxcarbazepine, 10-hydroxycarbazepine, and zonisamide by HPLC-UV and a rapid GC method using a nitrogenphosphorus detector for levetiracetam. J Chromatogr Sci 2007; 45: 616-622
77. Greiner C, Haen E. Development of a simple column-switching highperformance liquid chromatography (HPLC) method for rapid and simultaneous routine serum monitoring of lamotrigine, oxcarbazepine and 10- monohydroxycarbazepine (MHD). J Chromatogr B Analyt Technol Biomed Life Sci 2007; 854: 338-344
78. Beck O, Ohman I, Nordgren HK. Determination of lamotrigine and its metabolites in human plasma by liquid chromatography-mass spectrometry. Ther Drug Monit 2006; 28: 603-607
79. Westley IS, Morris RG. Seradyn quantitative microsphere system lamotrigine immunoassay on a Hitachi 911 analyzer compared with HPLC-UV. Ther Drug Monit 2008; 30: 634-637
80. Morris RG, LeeMY, Cleanthous X, et al. Long-term follow-up using a higher target range for lamotrigine monitoring. Ther Drug Monit 2004; 26: 626-632
81. Patsalos PN, Berry DJ, Bourgeois BF, et al. Antiepileptic drugs-best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies. Epilepsia 2008; 49: 1239-1276